Japan’s Eisai aims to roll out its groundbreaking Alzheimer’s drug Leqembi to 1,500 people in China later this year, but expects growth to accelerate significantly in 2025 as diagnosis methods change, ...
-
-
Recent Updates
- China AI Firms Watch as Nvidia Suppliers Prepare for a Possible Huang Exit
- China AI Firms Watch as Nvidia Suppliers Prepare for a Possible Huang Exit
- Nvidia Succession Fears Hit China and Asian AI Supply Chains
- Nvidia Succession Fears Hit China and Asian AI Supply Chains
- Nvidia Succession Fears Hit China and Asian AI Supply Chains
- Hong Kong Regulators Push Tokenized Finance Toward 24-Hour Trading
- Hong Kong Regulators Push Tokenized Finance Toward 24-Hour Trading
- Hong Kong Regulators Push Tokenized Finance Toward 24-Hour Trading
- China Spy Allegations Put Nvidia CEO Jensen Huang in the Spotlight
- China Spy Allegations Put Nvidia CEO Jensen Huang in the Spotlight
Blogroll